Effects of phosphodiesterase type 5 inhibitor on pulmonary hemodynamics in the patients with high altitude pulmonary hypertension (results of 12 week randomized, blind, placebo-controlled study) Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005
Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Dexamethasone reduces pulmonary artery pressure in lowlanders with COPD travelling to 3200m. A randomized, placebo-controlled trial Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension}, Source: Eur Respir J 2012; 40: 874-880 Year: 2012
Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017
Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with precapillary pulmonary hypertension and sleep disturbed breathing. Randomized, double-blind, cross-over trial Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Effect of acetazolamide on pulmonary hemodynamics in COPD-patients going to altitude: a randomized trial Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019
Effects of fasudil in patients with high-altitude pulmonary hypertension Source: Eur Respir J 2012; 39: 496-498 Year: 2012
Acute hemodynamic effect of acetazolamide in patients with pulmonary hypertension whilst breathing normoxic and hypoxic air: a randomized cross-over trial Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021
Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012
Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN) Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal Source: International Congress 2017 – PAH and CTEPH Year: 2017
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical Trials: "Aerosolized Lancovutide (Moli1901)" and "Oral Sildenafil" Year: 2009
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015